Recent evidence reports that injection of synthetic antitumor miRNAs successfully inhibits tumor metastasis in animal models [46], which sheds light on the exploitation of miR-23b based therapies to treat metastatic TSCC with IL-17A upregulation. Here, IL17A is linked to neoplasm.